| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Oct 18, 2006 |
Director, Chief Exec Officer & President, Ten Percent Owner
Trans History: 442
|
Director, Chief Exec Officer & President, Ten Percent Owner | Form 4 | Other acquisition or disposition | -- | -- | 1,710,790 |
| Oct 18, 2006 |
Director, Chief Exec Officer & President, Ten Percent Owner
Trans History: 442
|
Director, Chief Exec Officer & President, Ten Percent Owner | Form 4 | Other acquisition or disposition | -- | -- | 29,275 |
| Oct 18, 2006 |
Director, Chief Exec Officer & President, Ten Percent Owner
Trans History: 442
|
Director, Chief Exec Officer & President, Ten Percent Owner | Form 4 | Other acquisition or disposition | -- | -- | 29,275 |
| Oct 17, 2006 |
Director
Trans History: 480
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 10,000 | $9.88 | 42,000 |
| Oct 17, 2006 |
Director
Trans History: 480
|
Director | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 5,531 | $17.85 | 36,469 |
| Oct 17, 2006 |
Director
Trans History: 480
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 10,000 | -- | -- |
| Oct 17, 2006 |
Director, Chief Exec Officer & President, Ten Percent Owner
Trans History: 442
|
Director, Chief Exec Officer & President, Ten Percent Owner | Form 4 | Open market or private sale of non-derivative or derivative security | 28,656 | $18.00 | 63,009 |
| Oct 17, 2006 |
Director, Chief Exec Officer & President, Ten Percent Owner
Trans History: 442
|
Director, Chief Exec Officer & President, Ten Percent Owner | Form 4 | Open market or private sale of non-derivative or derivative security | 1,344 | $18.05 | 61,665 |
| Oct 02, 2006 |
SVP, Clinical Development
Trans History: 208
|
SVP, Clinical Development | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 25,572 | -- | 25,572 |
| Oct 02, 2006 |
SVP, Clinical Development
Trans History: 208
|
SVP, Clinical Development | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 74,428 | -- | 74,428 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.